Quarterly report pursuant to Section 13 or 15(d)

CONVERTIBLE DEBT - Marpai Health Convertible Notes - 2020 Convertible Notes (Details)

v3.21.2
CONVERTIBLE DEBT - Marpai Health Convertible Notes - 2020 Convertible Notes (Details)
9 Months Ended 12 Months Ended
Jul. 29, 2021
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
item
Debt Instrument [Line Items]        
Cash proceeds from issuance of convertible notes   $ 550,000 $ 2,000,000  
Term of debt 6 months      
2020 Convertible Notes        
Debt Instrument [Line Items]        
Number of tranches of convertible debt agreements | item       3
Aggregate principal amount       $ 4,125,000
Cash proceeds from issuance of convertible notes       1,775,000
Notes issued in exchange for legal services provided       $ 50,000
Term of debt       2 years
Minimum gross proceeds of equity financing required for automatic conversion of notes       $ 2,000,000
IPO Price As Percentage Of Per Share Public Offering Price Stated In The Final Prospectus       70.00%
Number of times the note amount, plus any accrued and unpaid interest payable upon change in control | item       1.5
Interest rate       8.00%
First tranche        
Debt Instrument [Line Items]        
Aggregate principal amount       $ 800,000
Price per share determined based on maximum pre-money valuation on a fully diluted basis       $ 8,000,000
Price per share determined based on discount on lowest price per share paid by the investors in financing round       20.00%
Second tranche        
Debt Instrument [Line Items]        
Aggregate principal amount       $ 1,500,000
Price per share determined based on maximum pre-money valuation on a fully diluted basis       $ 16,000,000
Price per share determined based on discount on lowest price per share paid by the investors in financing round       20.00%
Third tranche        
Debt Instrument [Line Items]        
Aggregate principal amount       $ 1,900,000
Cash proceeds from issuance of convertible notes       75,000
Price per share determined based on maximum pre-money valuation on a fully diluted basis       $ 35,000,000
Price per share determined based on discount on lowest price per share paid by the investors in financing round       30.00%